Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension

Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension

WILMINGTON, Del.--(BUSINESS WIRE)--Oct 7, 2025-

AstraZeneca Reports Positive Phase III Bax24 Results, Reinforcing Baxdrostat’s Potential as a Novel Treatment for Hard-to-Control Hypertension

AstraZeneca Reports Positive Phase III Bax24 Results, Reinforcing Baxdrostat’s Potential as a Novel Treatment for Hard-to-Control Hypertension (IN BRIEF) AstraZeneca reported positive Phase III Bax24 trial results showing that baxdrostat achieved a significant and clinically meaningful reduction in 24-hour ambulatory systolic blood pressure in patients with treatment-resistant hypertension. The once-daily oral therapy was well tolerated and main…

24‑hour SBP reduced: AstraZeneca's baxdrostat meets Bax24 Phase III primary endpoint, effective across day including morning

Baxdrostat (2mg) met the Bax24 Phase III primary endpoint, significantly reducing ambulatory 24‑hour SBP vs placebo in 218 randomized rHTN patients. Data to be presented at AHA Nov 2025; half-life up to ~30 hours.